00:02You're listening to AI Prism from Seoul Economic Daily.
00:06Korea's job market just got three new signals worth reading closely.
00:11Samsung and SK Hynix are adding at least two more chip fabs in Gwangju by 2040,
00:17on top of four already planned. Korean robotics firms just landed 72 buyer meetings at a trade
00:24fair in Beijing, chasing a humanoid robot market Goldman Sachs says could grow six-fold by 2035.
00:31And a cancer vaccine breakthrough from Moderna and Merck just sent a signal to every biotech
00:37track graduate watching from Korea. It's Friday, August 21st. Let's look at what this means for
00:43job seekers and graduates in Korea. Samsung and SK Hynix told the government they now see clear
00:50enough demand to build the extra fabs, pushing Korea's projected 2040 power demand up sharply
00:57overnight. Korean robotics companies used the Korea-China Robot Week in Beijing to pitch
01:03component and control technology to more than 80 Chinese firms and investors.
01:08Moderna and Merck's personalized cancer vaccine, tested alongside Merck's Keytruda,
01:13delivered the first proven clinical benefit for an mRNA-based cancer treatment
01:18in a trial of over 1,100 high-risk melanoma patients. Here's what the numbers show.
01:25Samsung and SK Hynix's added fabs pushed Korea's projected 2040 peak power demand to as much as 165
01:35gigawatts, up from an April estimate of 138.2 gigawatts. Chip-related power demand alone jumped 20.6
01:45gigawatts beyond earlier forecasts, a shift the energy ministry says will require the equivalent
01:50of 19 additional nuclear reactors' worth of capacity. Korean robotics firms met 72 pre-matched
01:59buyers during the Beijing event. Part of a market Goldman Sachs now projects could reach $38 billion,
02:05or 52.97 trillion won, by 2035, up from a prior estimate of $6 billion, or 8.36 trillion won.
02:17Moderna and Merck's vaccine, branded Intismarin Autogene, meaningfully extended recurrence-free
02:24survival versus Keytruda alone, and the companies are running nine more trials across six cancer types.
02:32Moderna's stock jumped 177% to $174.38 on the trial results, the biggest single-day gain for any S
02:43&P 500
02:43stock in 25 years, while Merck rose 12.6% to a record $152.20. So what does this mean
02:54for job seekers
02:55and graduates in Korea? Earlier, we flagged the new Gwangju fabs. Here's what that means for you.
03:02Expect sustained hiring demand in semiconductor engineering, power infrastructure, and related
03:08supply chain roles well into the next decade, not just a short-term hiring spike.
03:14The Beijing trade results suggest Korean robotics and component makers are scaling up export operations,
03:20which could open more roles in hardware engineering and international business development.
03:26And if you're on a biotech or life sciences track, the mRNA cancer vaccine result signals that personalized
03:33medicine is moving from concept to commercial pipeline, worth watching as more trial data lands over the next
03:40one to two years. Three things to watch. How the government's 12th power supply plan allocates new capacity
03:49between nuclear, LNG, and renewables. Further, Beijing trade fair deal announcements from Korean
03:56robotics firms. And Moderna and Merck's non-small cell lung cancer trial results, expected within the
04:03next one to two years. That's today's AI Prism, students and grads. This episode was produced with AI
04:11assistance based on Seoul Economic Daily reporting and reviewed by a human editor. AI Prism is a
04:18won-ifra award-winning series. We'll be back tomorrow. You've been listening to AI Prism from Seoul Economic Daily.
댓글